- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Erdostein has an antioxidant effect and carries free radicals. In particular, erdostein protects the respiratory tract from the damaging effects of cigarette smoke against alpha-1-antitrypsin inactivation.
Erdostein increases the concentration of immunoglobulin A (IgA) in the mucous membrane of the respiratory tract in patients with chronic obstructive respiratory diseases, and also reduces the inhibitory effect of tobacco smoke on the function of granulocytes.
The effect of erdosteine therapy develops after 3-4 days of treatment. Erdostein per se does not contain free SH-radicals, therefore it does not have a damaging effect on the gastrointestinal tract, and the side effects of the digestive system do not differ from those of placebo.
Erdostein is rapidly absorbed from the gastrointestinal tract and is metabolized in the liver to three active metabolites, the most important of which is N-thiodiglycolyl-homocysteine (Metabolite 1 or M1). The half-life (T1 / 2) is more than 5 hours. Repeated use of erdostein or food intake does not affect the pharmacokinetic parameters. The maximum concentration (Cmax) in the blood plasma is 3.46 mcg / ml, the time to reach the maximum concentration (Tmax) is 1.48 hours, the area under the concentration-time curve (AUC0-24h) is 12.09.
Erdostein binds to plasma proteins by 64.5%. Excreted in the form of inorganic sulfates through the kidneys and intestines.
In case of abnormal liver function, an increase in indicators is observed: the maximum concentration (Cmax) and the area under the concentration-time curve (AUC).
An increase in the half-life (T1 / 2) is possible with marked impaired liver function.
In renal failure, accumulation of metabolites is possible.
Diseases of the respiratory tract with the formation of viscous sputum (in complex therapy).
Excipients: microcrystalline cellulose - 13 mg, povidone (K-30) - 8 mg, magnesium stearate - 3 mg.
Hard gelatin capsules: the body and cap of the capsule - titanium dioxide - 1.3333%, the quinoline yellow dye - 0.9197%, the sunset sunset sunflower yellow - 0.0044%, gelatin - up to 100%.
No customer reviews for the moment.
Dosage and Administration
1 capsule (300 mg), 2 times a day.
If there is no improvement within 5 days after the start of the use of the drug or if there is a deterioration, you should contact your doctor.
The incidence of adverse reactions is according to the WHO classification: very often (≥1 / 10 cases), often (≥1 / 100 and <1/10 cases), infrequently (≥1 / 1000 and <1/100 cases), rarely (≥ 1/10000 and <1/1000 cases) and very rarely (<1/10000 cases), the frequency is unknown.
From the gastrointestinal tract: rarely - heartburn, nausea, diarrhea; very rarely, nausea, epigastric pain, loss or change in taste sensitivity at the beginning of treatment.
On the part of the skin and subcutaneous tissues: rarely - allergic reactions: redness of the skin, edema, eczema; angioedema.
Violations of the respiratory system, chest and mediastinum; very rarely - shortness of breath.
Hypersensitivity to the components that make up the drug.
Children's age up to 18 years.
Homocysteinuria (the drug is a source of homocysteine, therefore, disorders of amino acid metabolism are possible in patients on a diet with a reduced content of free methionine).
Pregnancy (I trimester).
The drug should be prescribed with caution to patients with marked violations of the liver; with diseases of the bronchi, accompanied by excessive accumulation of secretions.
With simultaneous use of erdostein increases the concentration of amoxicillin in the bronchial secretion, which allows for a faster response to therapy compared to amoxicillin monotherapy.
During treatment it is necessary to take a sufficient amount of liquid, which increases the expectorant effect. In cases of impaired motility of the bronchi or with a significant amount of sputum, the use of the drug requires caution, due to the risk of delayed discharge in the respiratory tract and an increased risk of attaching infection or bronchospasm.
Influence on ability to steer vehicles, mechanisms
It does not affect the ability to drive vehicles, mechanisms and engage in other activities that require increased concentration of attention and psychomotor speed.
No cases of overdose have been reported. However, in cases of overdose or in case of accidental use by children, gastric lavage and symptomatic therapy are recommended.
- Brand name: Elmucin
- Active ingredient: Erdostein
- Dosage form: Capsules
- Manufacturer: Piq-Pharma
- Erdosteine modulates radiocontrast-induced hepatotoxicity in rat
- The effects of erdosteine, N-acetylcysteine and vitamin E on nicotine-induced apoptosis of cardiac cells
- Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats
- Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner
- The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of hippocampal neural cells
- Sensitive determination of erdosteine in human plasma by use of automated 96-well solid-phase extraction and LC–MS/MS
- Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine
- The activities of tissue xanthine oxidase and adenosine deaminase and the levels of hydroxyproline and nitric oxide in rat hearts subjected to doxorubicin: protective effect of erdosteine
- High-performance liquid chromatographic determination of erdosteine and its optical active metabolite utilizing a fluorescent chiral tagging reagent, R-(−)-4-(N,N-dimethylaminosulfonyl)-7-(3-aminopyrrolidin-1-yl)-2,1,3-benzoxadiazole
- Depressant Effects of Ambroxol and Erdosteine on Cytokine Synthesis, Granule Enzyme Release, and Free Radical Production in Rat Alveolar Macrophages Activated by Lipopolysaccharide
- The protective effect of erdosteine on radiocontrast induced nephrotoxicity in rats
- Effects of erdosteine on sputum biochemical and rheologic properties: Pharmacokinetics in chronic obstructive lung disease
- The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells
- Protein oxidation and lipid peroxidation after renal ischemia-reperfusion injury: protective effects of erdosteine andN-acetylcysteine
- Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction
- The protective effect of erdosteine against ototoxicity induced by cisplatin in rats
- Erdosteine: Antitussive and Anti-inflammatory Effects
- Erdosteine Prevents Colonic Inflammation Through Its Antioxidant and Free Radical Scavenging Activities
- The effects of isoniazid on hippocampal NMDA receptors: Protective role of Erdosteine
- Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats
- The protective role of erdosteine on testicular tissue after testicular torsion and detorsion
- Erdosteine Against Acetaminophen Induced Renal Toxicity
- Effects of erdosteine on bleomycin-induced lung fibrosis in rats